[
  {
    "id": "pemphigoid_29602_1750166913.txt-1",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Definition / general",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#definitiongeneral484871",
    "clean_content": "Definition / general\n\n* Chronic, immune mediated, subepithelial blistering disease that predominantly affects mucous membranes* Autoantibodies directed at components of the basement membrane zone"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-2",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Essential features",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#essentialfeatures484872",
    "clean_content": "Essential features\n\n* Second most common immune mediated, subepithelial blistering disease, after bullous pemphigoid ([J Invest Dermatol 2016;136:2495](27456755))* Most often presents in the oral cavity* Autoimmune (IgG, IgA or C3) attack of hemidesmosomes / basement membrane zone* May affect the oral cavity, conjunctiva, subglottis, larynx, nose, esophagus, penis, vulva, anal mucosa or skin"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-3",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Terminology",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#terminology484873",
    "clean_content": "Terminology\n\n* Mucous membrane pemphigoid* Benign mucous membrane pemphigoid (BMMP)* Cicatricial pemphigoid* Mucosal pemphigoid"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-4",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "ICD coding",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#icdcoding484874",
    "clean_content": "ICD coding\n\n* ICD-10: [L12.1](https://www.icd10data.com/ICD10CM/Codes/L00-L99/L10-L14/L12-/L12.1) - benign mucous membrane pemphigoid"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-5",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Epidemiology",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#epidemiology484875",
    "clean_content": "Epidemiology\n\n* Wide age range; predilection for middle aged to older adults* Slight female predominance"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-6",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Sites",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#sites484876",
    "clean_content": "Sites\n\n* Affects the oral cavity (96.7%), conjunctiva (42.2%), subglottis, larynx, nose, esophagus, skin or anogenital regions (27.9%) ([J Eur Acad Dermatol Venereol 2016;30:72](26446477))* Oral cavity is the most commonly affected site\n    + Gingiva > buccal mucosa > palate > alveolar ridge > tongue > lower lip"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-7",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Pathophysiology / etiology",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#pathophysiologyetiology484877",
    "clean_content": "Pathophysiology / etiology\n\n* Likely an autoantibody induced and complement mediated sequestration of leukocytes (predominantly neutrophils) with release of cytokines and leukocyte enzymes leading to detachment of epithelium at the basement membrane zone ([Br J Oral Maxillofac Surg 2008;46:358](17804127))* Combination of IgG (94.6%), C3 (85.8%) or IgA (16.5%) autoantibodies directed against epithelial basement membrane zone components BP180, BP230, alpha 6 integrin, beta 4 integrin or laminin 332 (laminin-5) ([J Eur Acad Dermatol Venereol 2016;30:72](26446477), [Acta Derm Venereol 2004;84:381](15370705))\n    + BP180 is the most frequently affected target, in ~75% ([Br J Dermatol 2006;154:90](16403100))+ Oral only subset: α6 integrin target antigen ([Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:37](9474612))+ Ocular only subset: β4 integrin ([J Invest Dermatol 2006;126:2631](16810295))* Mechanism that links the binding of autoantibodies to the basement membrane zone and the subsequent scarring process is unknown ([Clin Dermatol 2012;30:34](22137224))* Association with HLA-DQB1\\*0301 ([Br J Dermatol 2001;145:805](11736906), [Br J Dermatol 2001;145:406](11531829), [Br J Oral Maxillofac Surg 2008;46:358](17804127))* Emerging association with anti-PDL1 medications ([Front Med (Lausanne) 2018;5:268](30320114), [J Immunother 2019;42:359](31246641), [J Eur Acad Dermatol Venereol 2019 Oct 29 [Epub ahead of print]](31660663), [Br J Dermatol 2018;179:993](29758087))"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-8",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Diagrams / tables",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#diagramstables484878",
    "clean_content": "Diagrams / tables\n\n*Images hosted on other servers:*  \n\n[![Missing Image](https://www.pathologyoutlines.com/thumb/oralcavitypemphigoidotherimg01.jpg)](https://www.semanticscholar.org/paper/Pemphigoid-diseases-Schmidt-Zillikens/fa66a8376c0cb386f0fe7ca92f32ca47f4a69026/figure/0)\n\nEpidermal / dermal junction\n\n[![Missing Image](https://www.pathologyoutlines.com/thumb/oralcavitypemphigoidotherimg02.jpg)](https://www.jaad.org/article/S0190-9622(14)01871-4/fulltext)\n\nTable 2 MMPDA Index"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-9",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Clinical features",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#clinicalfeatures484879",
    "clean_content": "Clinical features\n\n* General: erythematous or ulcerated mucous membranes +/- blood blister formation (+ Nikolsky sign); periodic episodes leading to potential scarring ([Br J Oral Maxillofac Surg 2008;46:358](17804127))* Ocular: scarring on the conjunctiva may produce a symblepharon or blindness* Oropharynx: dyspnea, hoarseness* Esophagus: difficulty swallowing or bleeding; stenosis* Nose: nosebleeds* Skin: rare; vesicles / bullae* Laryngeal involvement can lead to airway loss"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-10",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#diagnosis484880",
    "clean_content": "Diagnosis\n\n* Diagnosis made on routine H&E histological examination and biopsy for direct immunofluorescence* Direct immunofluorescence is gold standard for diagnosis* Cases may be followed with indirect immunofluorescence, immunoblotting or enzyme-linked immunosorbent assay (ELISA) testing* 2015 consensus group created a disease area index table to standardize diagnosis ([J Am Acad Dermatol 2015;72:168](25443626))"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-11",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Laboratory",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#laboratory484881",
    "clean_content": "Laboratory\n\n* IgG autoantibodies against basement membrane zone components (BP180, BP230, alpha 6 integrin, beta 4 integrin or laminin 332) detected* IgG titers correlate with disease severity ([Br J Dermatol 1999;140:645](10233314))* Laminin-332 is detected in up to 20% of patients ([J Invest Dermatol 2001;116:348](11180014), [Br J Dermatol 2019;180:149](30216412))"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-12",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Prognostic factors",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#prognosticfactors484882",
    "clean_content": "Prognostic factors\n\n* Detection of both IgG and IgA autoantibodies associated with more severe disease ([Br J Dermatol 1998;138:602](9640363))* Laminin-332 is associated with more severe disease and solid organ tumors in up to 30% ([J Invest Dermatol 2001;116:348](11180014), [Br J Dermatol 2019;180:149](30216412))"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-13",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Case reports",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#casereports484883",
    "clean_content": "Case reports\n\n* 58 year old man presents with painful mouth sores, cutaneous blisters, paronychia and onychomadesis ([BMC Dermatol 2019;19:3](30674299))\n  * 83 year old patient presenting with oral blisters and erosions after taking pembrolizumab ([Front Med (Lausanne) 2018;5:268](30320114))"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-14",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Treatment",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#treatment484884",
    "clean_content": "Treatment\n\n* Mild-to-moderate disease:\n  + Topical therapies, including betamethasone, fluticasone propionate or clobetasol propionate+ Dapsone ([Br J Oral Maxillofac Surg 2008;46:358](17804127)) or sulfapyridine\n\n* Moderate-to-severe disease:\n  + Mycophenolate mofetil, azathioprine, sulfa drug or prednisolone\n\n* Severe, recalcitrant disease:\n  + Pulsed IV cyclophosphamide, IV immunoglobulin and rituximab ([Clin Exp Dermatol 2019;44:732](31102296))* Rituximab (anti-CD20 therapy) in combination with conventional immunosuppressive therapy leads to more rapid and sustained disease control with fewer potential adverse events ([J Am Acad Dermatol 2016;74:835](26936298))* Encourage excellent oral hygiene habits and regular ophthalmologic examinations"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-15",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Clinical images",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#clinicalimages484885",
    "clean_content": "Clinical images\n\nContributed by Molly Housley Smith, D.M.D. and Sonal Tuli, M.D.  \n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith01new.jpg)](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith01new.jpg)\n\nDiffuse gingival involvement\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith02new.jpg)](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith02new.jpg)\n\nLocalized gingival ulceration\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith03new.jpg)](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith03new.jpg)\n\nBullae development\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith04new.jpg)](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith04new.jpg)\n\nBuccal mucosa involvement\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidTuli01new.jpg)](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidTuli01new.jpg)\n\nSymblepharon"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-16",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Gross description",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#grossdescription484886",
    "clean_content": "Gross description\n\n* Thin wedge of white-tan surface epithelium with underlying tan-brown connective tissue* Epithelium occasionally separated from underlying connective tissue"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-17",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Microscopic (histologic) description",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#microscopichistologicdescription484887",
    "clean_content": "Microscopic (histologic) description\n\n* Surface epithelium cleanly detached from the underlying connective tissue at the point of the basement membrane zone* Superficial lamina propria contains a variable amount of inflammation that may contain lymphocytes, eosinophils and neutrophils ([Br J Oral Maxillofac Surg 2008;46:358](17804127))* Aggregates of erythrocytes may be present in area of bullae formation"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-18",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Microscopic (histologic) images",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#microscopichistologicimages484888",
    "clean_content": "Microscopic (histologic) images\n\nContributed by Molly Housley Smith, D.M.D. and [@reportesVilla](https://twitter.com/reportesVilla) on Twitter  \n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith05new.jpg)](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith05new.jpg)\n\nSubepithelial separation\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith06new.jpg)](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith06new.jpg)\n\nSubepithelial cleft   \ncontains fibrin,   \nerythrocytes and   \ninflammatory cells\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith12new.jpg)](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith12new.jpg)\n\nSubepithelial separation\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith08new.jpg)](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith08new.jpg)\n\nMinimal inflammation\n\n[![Pemphigoid](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidreportesVilla01.jpg)](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidreportesVilla01.jpg)\n\nPemphigoid"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-19",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Immunofluorescence description",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#immunofluorescencedescription484889",
    "clean_content": "Immunofluorescence description\n\n* Direct immunofluorescence (DIF): linear deposits of IgG, IgA or C3 along the basement membrane zone ([Br J Oral Maxillofac Surg 2008;46:358](17804127))* Indirect immunofluorescence (IIF): IgG autoantibodies against the basement membrane zone with known target antigens including BP180, BP230, alpha 6 integrin, beta 4 integrin or laminin 332 (laminin-5)"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-20",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Immunofluorescence images",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#immunofluorescenceimages484890",
    "clean_content": "Immunofluorescence images\n\nContributed by Molly Housley Smith, D.M.D.  \n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith09new.jpg)](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith09new.jpg)\n\nIgG\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith10new.jpg)](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith10new.jpg)\n\nC3\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith11new.jpg)](https://www.pathologyoutlines.com/imgau/oralcavitypemphigoidHousleySmith11new.jpg)\n\nIgA"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-21",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Videos",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#videos484891",
    "clean_content": "Videos\n\nClinical, histology, laboratory findings with discussion on pathophysiology"
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-22",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Sample pathology report",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#samplepathologyreport484892",
    "clean_content": "Sample pathology report\n\n* Buccal gingiva, incisional biopsy:\n  + Subepithelial vesiculo-erosive condition consistent with benign mucous membrane pemphigoid (see comment)+ Comment: On H&E, there is a clean separation of the superficial stratified squamous epithelium from the underlying connective tissue at the layer of the basement membrane zone. On direct immunofluorescence, a shaggy and linear deposition of IgG, C3 and IgA is present in the basement membrane zone."
  },
  {
    "id": "pemphigoid_29602_1750166913.txt-23",
    "source_document": "pemphigoid_29602_1750166913.txt",
    "parent": "oral-cavity-amp-oropharynx_84",
    "parent_url": "",
    "topic": "Differential diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/oralcavitypemphigoid.html#differentialdiagnosis484893",
    "clean_content": "Differential diagnosis\n\n* [Bullous pemphigoid (BP)](https://www.pathologyoutlines.com/topic/skinnontumorbullouspemphigoid.html)\n  + Most common immune mediated, subepithelial blistering disease+ Widespread skin lesions+ Persistent mucosal lesions are not seen+ Propensity to scar is less frequent+ Infrequent in the oral cavity\n\n* [Pemphigus vulgaris](https://www.pathologyoutlines.com/topic/oralcavitypemphigus.html)\n  + Autoimmune bullous disease directed against desmosomes+ Skin lesions heal without scarring+ Buccal mucosa > palate > tongue > labial mucosa > gingiva+ Suprabasilar clefting with acantholysis+ Direct immunofluorescence shows intracellular [IgG](https://www.pathologyoutlines.com/topic/stainsIgA.html) and **C3** staining+ Enzyme-linked immunosorbent assay demonstrates antibodies directed against **desmoglein** 1 and 3\n\n* [Paraneoplastic pemphigus](https://www.pathologyoutlines.com/topic/skinnontumorpemphigus.html)\n  + Autoimmune blistering condition that indicates an underlying benign or malignant disease+ Patient may be unwell at time of diagnosis+ Intraepidermal-acantholytic bullae+ Direct immunofluorescence may demonstrate intracellular or basement membrane zone [IgG](https://www.pathologyoutlines.com/topic/stainsIgA.html) and **C3** staining+ Immunoblotting reveals antibodies to desmoglein 3 (Dsg3), BP230, envoplakin, plectin, periplakin or epiplakin\n\n* [Erosive lichen planus](https://www.pathologyoutlines.com/topic/oralcavitylichenplanus.html)\n  + T-cell mediated autoimmune disease+ Interface mucositis with Civatte bodies+ Subepithelial band of lymphocytes+ Direct immunofluorescence shaggy fibrin deposition at basement membrane zone\n\n* [Linear IgA disease](https://www.pathologyoutlines.com/topic/skinnontumorlineariga.html)\n  + Rare immune mediated, subepithelial blistering disease+ Mainly on skin; oral lesions less common+ Demonstrates prominent linear IgA deposition (+/- [IgG](https://www.pathologyoutlines.com/topic/stainsIgA.html) or [IgM](https://www.pathologyoutlines.com/topic/kidneyIgM.html)) along basement membrane zone on direct immunofluorescence\n\n* [Epidermolysis bullosa acquisita](https://www.pathologyoutlines.com/topic/skinnontumoreba.html)\n  + Immune mediated, subepithelial blistering condition+ Differentiate using salt split testing or enzyme-linked immunosorbent assay+ Enzyme-linked immunosorbent assay detects antibodies against type VII collagen+ Antibodies bind to the connective tissue floor of the bullae in epidermolysis bullosa acquista rather than the roof of the bullae as seen in metalloproteinases\n\n* [Lichen planus pemphigoides](https://www.pathologyoutlines.com/topic/skinnontumorlichenplanus.html)\n  + Generally younger+ Lichenoid lesions along with bullae+ Also has lichenoid characteristics+ Similar direct immunofluorescence with [IgG](https://www.pathologyoutlines.com/topic/stainsIgA.html), **C3** or IgA+ at basement membrane zone\n\n* **Bullous lichen planus**\n  + Least common variant of oral lichen planus+ Extremely rare+ Demonstrates clinical features similar to lichen planus and lichen planus pemphigoides; vesicles or bullae on pre-existing lichen planus lesions+ Histopathologic and immunofluorescent antibody studies are similar to lichen planus\n\n* **Angina bullosa hemorrhagica**\n  + Often traumatic in nature+ Blood filled blisters on the soft palate+ Can be a mimicker on H&E+ Direct immunofluorescence is usually negative ([Dermatol Reports 2014;6:5282](25386327))\n\n* [Erythema multiforme](https://www.pathologyoutlines.com/topic/oralcavityerythemamultiforme.html)\n  + Self limiting blistering condition+ Lesions typically last 2 - 4 weeks+ Triggers may include infections (HSV, mycoplasma) or medications+ May demonstrate target lesions on the skin+ Lichenoid infiltrate in basement membrane zone+ Epithelium is edematous and spongiotic with necrosis of basal and suprabasal epithelial cells (intraepithelial and subepithelial bullae formation)+ Direct immunofluorescence shows diffuse granular staining of **C3** in basement membrane zone"
  }
]